

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis [ID1581]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

During scoping, it was acknowledged that in the related appraisal of [rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis](#) (TA308), the committee considered that cyclophosphamide reduces fertility in both men and women. But it understood that the peak age of onset for ANCA-associated vasculitis is between 60 and 70 years. The committee concluded that number of people with ANCA-associated vasculitis who have not completed their family is likely to be small.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No other issues raised.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

The committee understood the issue that was raised in TA308. The committee for the avacopan appraisal noted that avacopan is proposed as

an add-on to standard care. It considered that its recommendation for avacopan would not impact prescription rates for cyclophosphamide. It therefore concluded that its recommendation for avacopan would not have a different impact on people protected by the equality legislation than on the wider population.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, in section 3.16 of the ACD.

Approved by Associate Director (name): ...Linda Landells.....

Date: 19 July 2022

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?
No additional potential equality issues raised during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Yes, section 3.14 of the FAD.

Approved by Associate Director (name): Linda Landells.....

Date: 19 July 2022